Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

They Are Young And Need The Job: A Second Chance For Dangerous T-cells
The immune system"s T-cells react to foreign protein fragments and therefore are crucial to combating viruses and bacteria. Errant cells that attack the body"s own material are in most cases driven to cell death. Some of these autoreactive T-cells, however, undergo a kind of reeducation to become "regulatory T-cells" that keep other autoreactive T-cells under control. A group led by immunologist Professor Ludger Klein of LMU Munich has now shown that the developmental stage of an autoreactive T-cell is decisive to its ultimate destiny. Young autoreactive T cells are very readily reeducated into regulatory T-cells. Under identical conditions, however, older T cells become fully activated and can cause damage they are in a way resistant to reeducation. "We now intend to study at the molecular level what makes a T-cell accessible for reeducation," said Klein, "because then it may be possible to convert even normal adult T-cells, which can be obtained easily and in great numbers from blood. Possibly, they could then be used as regulatory T-cells in therapies for autoimmune diseases such as type-1 diabetes or multiple sclerosis: these are diseases that are triggered by uncontrolled autoreactive T-cells." (PNAS, 10 June 2009)
generic viagra online
Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced results from a Phase 1 cardiac safety study of picoplatin, a new generation platinum-based chemotherapy agent and the Company"s lead product candidate. The Company worked collaboratively with the U.S. Food and Drug Administration (FDA) to design this study, which is required for new chemical entities.
plastic surgery before after
News of the day
Seeking Solutions To The Chronic Nursing Shortage In Canada And The US
The Arthur Labatt Family School of Nursing at The University of Western Ontario has announced a $2 million research chair to address issues surrounding the chronic shortage of registered nurses in Canada and the United States. Dr. Heather Laschinger, Ph.D., was named the first Arthur Labatt Family Nursing Research Chair in Human Re Optimization.
Oncology

Study Shows Januvia(TM) (sitagliptin) Offered Significant Blood Sugar-Lowering Efficacy In Combination With Insulin In Type 2 Diabetes

A new investigational study presented at the American Diabetes Association (ADA) 69th Annual Scientific Sessions showed that "Januvia" (sitagliptin), when added to ongoing insulin therapy with or without metformin, significantly improved blood sugar control.[i] Applications to use "Januvia" and "Janumet"* (sitagliptin/metformin) in combination with insulin have been accepted for review by the European Medicines Agency (EMEA) and by the U.S. Food and Drug Administration (FDA) and are currently under review. "Due to the progressive nature of the disease, over time most type 2 diabetes patients require multiple drugs to achieve glycemic control," said John Amatruda, M.D., Senior Vice President and Franchise Head, Diabetes and Obesity, Merck & Co., Inc. "If approved for use with insulin, sitagliptin and the fixed-dose combination of sitagliptin and metformin will be additional options for patients with type 2 diabetes who are taking insulin and whose blood sugar is not at goal." * Note, "Janumet" is not available in some countries yet, such as the UK. Sitagliptin is a highly selective, once-daily DPP-4 inhibitor that enhances a natural body system called the incretin system, to help regulate blood sugar by increasing levels of active GLP-1 and GIP hormones; it inhibits DPP-4 over 24 hours.[ii] The fixed dose combination of sitagliptin and metformin targets all three key defects of diabetes: insulin deficiency from pancreatic beta cells, insulin resistance, and overproduction of glucose by the liver.[iii] Sitagliptin is the first approved medicine in the DPP-4 inhibitor class of oral treatments. It has been approved in over 80 countries and to-date, there have been more than 11.1 million prescriptions dispensed worldwide.[iv] Study of addition of sitagliptin to ongoing insulin therapy with or without metformin1 In a 24-week study of 564 patients on long-acting, intermediate-acting or pre-mixed insulin, with or without metformin, the addition of sitagliptin (n=281) reduced HbA1c** by 0.6 percent (pAbout sitagliptin Sitagliptin is a member of a class of oral anti-hyperglycaemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors and is licensed for the treatment of type 2 diabetes in combination with either metformin and/or a sulphonylurea, or in certain patients, with a PPARy agonist (i.e. thiazolidinedione), when diet and exercise plus the other agent(s) do not provide adequate glycaemic control. Sitagliptin enhances the body"s own ability to lower blood sugar levels by increasing the levels of the body"s own active incretins, called GLP-1 and GIP. 2 The recommended dose of sitagliptin is 100mg once daily, with or without food, for all approved indications.2 Sitagliptin should not be used in patients with moderate or severe renal impairment or in patients with hepatic insufficiency and is contraindicated in patients with hypersensitivity to the active substances or to any of the excipients. The drug should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, or in woman who are lactating or pregnant. 2 References [i] Vilsboll T, Rosenstock JM, Yki-Jarvinen H et al. Sitagliptin, a selective DPP-4 inhibitor, improves glycemic control when added to insulin, with or without metformin, in patients with type 2 diabetes. Data presented at ADA Congress 2009, New Orleans [ii] JANUVIA European Public Assessment Report (EPAR), Product Information, 19/09/2008 Januvia-H-C-722-N-06 [iii] JANUMET European Public Assessment Report (EPAR), Product Information, 10/12/2008 Janumet BMS-H-C-861-IA-05. [iv] IMS Health, NPA™ Weekly, TRxs, week-ending October 20, 2006 through week-ending May 22, 2009 Data on file, Merck & Co Merck, Sharp & Dohme


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009